ABSTRACT
PURPOSE: To demonstrate the production of inflammatory mediators by cells located in bone marrow spaces inside rodent menisci. METHODS: Mice subjected to transection of the medial collateral and anterior cruciate ligaments and meniscotomy (osteoarthritis model) or to a sham procedure, as well as non-operated (naive) mice and rats, had knee joints excised. Tissues were stained with hematoxylin-eosin and tartrate-resistant acid phosphatase (TRAP). CD68+ cells, inducible nitric oxide synthase (iNOS), interleukin (IL)-1ß, and tumor necrosis factor (TNF) expression were detected using immunohistochemistry. RESULTS: Lamellar ossified areas, bone-entrapped osteocytes and bone marrow spaces were found inside menisci of one week up to 6 months-old naïve mice, regardless of gender. Menisci from naive rats also showed the same pattern with bone marrow areas. CD68+ cells were identified in bone marrow areas inside the meniscus of mice. TRAP+ osteoclasts, and hematogenous precursors expressing IL-1ß, TNF, and iNOS were identified inside bone marrow areas in meniscal samples from both naïve and sham operated mice. Quantitative immunoexpression of IL-1 ß, TNF and iNOS was more intense, P = 0.0194, 0.0293, 0.0124, respectively, in mouse knees from mice sacrificed 49 days after being subjected to an osteoarthritis (OA) model as compared to sham operated animals. CONCLUSION: We provide novel data showing that rodent menisci display bone marrow areas with cells able to produce inflammatory mediators. Immunoexpression of inflammatory mediators in those bone marrow areas is significantly more pronounced in mice subjected to experimental OA.
Subject(s)
Bone Marrow/pathology , Inflammation Mediators/metabolism , Meniscus/pathology , Osteoarthritis, Knee/metabolism , Animals , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Disease Models, Animal , Female , Interleukin-1beta/metabolism , Knee Joint/surgery , Male , Mice , Nitric Oxide Synthase Type II/metabolism , Osteoarthritis, Knee/pathology , Osteoclasts/metabolism , Rats , Rats, Wistar , Tartrate-Resistant Acid Phosphatase/metabolism , Tumor Necrosis Factor-alpha/metabolismABSTRACT
PURPOSE: To compare the outcomes of patients with an arthroscopic floating meniscus sign at 24-month follow-up when treated with and without medial compartment reconstruction surgery. Another aim of the present study was to compare magnetic resonance imaging and arthroscopic findings directly related to the characterization and localization medial collateral ligament (MCL) injuries. METHODS: A total of 112 patients diagnosed with combined anterior cruciate ligament (ACL)-MCL grade II injuries to be treated with ACL reconstruction surgery were included in the study. During arthroscopy, patients diagnosed with the "floating meniscus" sign were divided into 2 groups: group 1 (n = 58) was treated with ACL and medial compartment reconstruction surgery and group 2 (n = 54) was treated with ACL reconstruction and nonsurgical medial compartment treatment. Return to competitive sports (Tegner score), Lysholm scores, ACL reconstruction failure, and residual MCL laxity were evaluated 6, 12, and 24 months after surgery. RESULTS: After 24 months, patients from group 1 (n = 58) had an average Tegner score of 8.98 and Lysholm score of 89.67; 2 patients presented with ACL reconstruction failure and none presented with residual MCL laxity. Patients from group 2 (n = 54) had an average Tegner score of 6.7 and Lysholm score of 78.12; 16 patients presented with ACL reconstruction failure and 13 presented with residual MCL laxity. CONCLUSIONS: In the presence of a floating meniscus arthroscopic sign, patients with combined ACL and grade II MCL injuries treated with ACL and MCL reconstruction surgery had significantly lower frequency of ACL reconstruction failure, residual MCL laxity, and better Tegner and Lysholm scores at 24 months' follow-up (P < .05). Additionally, magnetic resonance imaging and arthroscopy differed significantly (P < .05) in their ability to identify mid-substance and tibial site MCL injuries. LEVEL OF EVIDENCE: Level I, randomized clinical trial.